Skip to search formSkip to main content

TL-118

Known as: Antiangiogenic Drug Combination TL-118 
A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a… Expand
National Institutes of Health

Related topics

Related topics

5 relations

Broader (5)

CimetidineCyclophosphamideDiclofenacDrug Combinations
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
TL-118 and Gemcitabine Drug Combination Display Therapeutic Efficacy in a MYCN Amplified Orthotopic Neuroblastoma Murine Model – Evaluation by MRI
Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2013
2013
TL-118—anti-angiogenic treatment in pancreatic cancer: a case report
Pancreatic cancer is one of the most aggressive malignant tumors. In recent years, little progress has been made in understanding… Expand
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice
Background:The poor prognosis of patients with colorectal-cancer liver metastases (CRLM) and the insufficiency of available… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE